Which Factors Are Relevant for Treatment Outcome in Dialectical Behaviour Therapy for Borderline Personality Disorder?
Vilka Faktorer påverkar Behandlingsutfall Vid Dialektisk Beteendeterapi för Borderline Personlighetssyndrom?
1 other identifier
observational
100
1 country
1
Brief Summary
The objective of this project is to investigate factors that contribute to the success and lack of success in DBT among individuals with BPD and a history of self-harm in a clinical psychiatric setting.
- 1.Do certain personality factors and identity disturbance predict the treatment outcome of DBT in individuals with BPD?
- 2.Do changes in identity disturbance, self-hate, or emotion regulation mediate the treatment outcome of DBT in individuals with BPD?
- 3.Do specific personality profiles moderate the treatment outcomes of DBT for individuals with BPD?
- 4.When does the primary treatment effect occur, and does this effect persist after a 12-month follow-up period?
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Sep 2023
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2023
CompletedFirst Submitted
Initial submission to the registry
October 24, 2023
CompletedFirst Posted
Study publicly available on registry
October 30, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 31, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 31, 2027
June 25, 2025
June 1, 2025
4 years
October 24, 2023
June 24, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Five Self-harm Behaviour Groupings Measure (5S-HM)
Indirect and direct self-harm
Treatment start, 3,6,9 and at end of treatment and at follow up at 24 months.
Secondary Outcomes (5)
The World Health Organization Disability Assessment Schedule II (WHODAS 2)
Treatment start, 3,6,9 and at end of treatment and at follow up at 24 months.
The Borderline Symptom List-23 (BSL-23)
Treatment start, 3,6,9 and at end of treatment and at follow up at 24 months.
The Level of Personality Functioning Scale-Brief Form 2.0 (LPFS 2.0)
Treatment start, 3,6,9 and at end of treatment and at follow up at 24 months.
The Personality Inventory for DSM-V Brief Form (PID-5-BF)
Treatment start, 3,6,9 and at end of treatment and at follow up at 24 months.
Hospitilization days
Treatment at end of treatment and at follow up at 24 months.
Study Arms (1)
Individuals with BPD
Individuals with BPD, as defined by the DSM-V, and a recent history (past 12 months) of self-harming behaviour.
Interventions
Standard Dialectical Behaviour Therapy of up to 12 months as described Professor Linehan
Eligibility Criteria
Adults with Borderline personality disorder in a specialized psychiatric setting. A majority of the individuals will have comorbid psychiatric conditions and have been offered other pharmacological and psychological treatments through their GP or a general psychiatric outpatient unit prior to the study intervention. Other treatments are permitted for inclusion in this study.
You may qualify if:
- Borderline personality disorder as defined by the DSM-V (assessed with SCID or uquivalent).
- Self-harm over the past 12 months
- Offered DBT at the Lund adult psychiatric clinic
You may not qualify if:
- Unable to read or communicate in Swedish
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Region Skanelead
- Department of Psychology. Lund University.collaborator
- University of Torontocollaborator
- Lund Universitycollaborator
Study Sites (1)
Lund adult psychiatric hospital
Lund, Skåne County, 22185, Sweden
Related Publications (17)
Alvarez-Tomas I, Ruiz J, Guilera G, Bados A. Long-term clinical and functional course of borderline personality disorder: A meta-analysis of prospective studies. Eur Psychiatry. 2019 Feb;56:75-83. doi: 10.1016/j.eurpsy.2018.10.010. Epub 2018 Dec 24.
PMID: 30599336BACKGROUNDvan Asselt AD, Dirksen CD, Arntz A, Severens JL. The cost of borderline personality disorder: societal cost of illness in BPD-patients. Eur Psychiatry. 2007 Sep;22(6):354-61. doi: 10.1016/j.eurpsy.2007.04.001. Epub 2007 Jun 4.
PMID: 17544636BACKGROUNDChen SY, Cheng Y, Zhao WW, Zhang YH. Effects of dialectical behaviour therapy on reducing self-harming behaviours and negative emotions in patients with borderline personality disorder: A meta-analysis. J Psychiatr Ment Health Nurs. 2021 Dec;28(6):1128-1139. doi: 10.1111/jpm.12797. Epub 2021 Sep 20.
PMID: 34519138BACKGROUNDCipriano A, Cella S, Cotrufo P. Nonsuicidal Self-injury: A Systematic Review. Front Psychol. 2017 Nov 8;8:1946. doi: 10.3389/fpsyg.2017.01946. eCollection 2017.
PMID: 29167651BACKGROUNDEllison WD, Rosenstein LK, Morgan TA, Zimmerman M. Community and Clinical Epidemiology of Borderline Personality Disorder. Psychiatr Clin North Am. 2018 Dec;41(4):561-573. doi: 10.1016/j.psc.2018.07.008. Epub 2018 Oct 16.
PMID: 30447724BACKGROUNDGad MA, Pucker HE, Hein KE, Temes CM, Frankenburg FR, Fitzmaurice GM, Zanarini MC. Facets of identity disturbance reported by patients with borderline personality disorder and personality-disordered comparison subjects over 20 years of prospective follow-up. Psychiatry Res. 2019 Jan;271:76-82. doi: 10.1016/j.psychres.2018.11.020. Epub 2018 Nov 10.
PMID: 30469092BACKGROUNDGratz KL, Bardeen JR, Levy R, Dixon-Gordon KL, Tull MT. Mechanisms of change in an emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Behav Res Ther. 2015 Feb;65:29-35. doi: 10.1016/j.brat.2014.12.005. Epub 2014 Dec 13.
PMID: 25557395BACKGROUNDWeekers LC, Hutsebaut J, Kamphuis JH. The Level of Personality Functioning Scale-Brief Form 2.0: Update of a brief instrument for assessing level of personality functioning. Personal Ment Health. 2019 Feb;13(1):3-14. doi: 10.1002/pmh.1434. Epub 2018 Sep 19.
PMID: 30230242BACKGROUNDKaufman EA, Meddaoui B. Identity pathology and borderline personality disorder: an empirical overview. Curr Opin Psychol. 2021 Feb;37:82-88. doi: 10.1016/j.copsyc.2020.08.015. Epub 2020 Aug 25.
PMID: 32932110BACKGROUNDKrueger RF, Derringer J, Markon KE, Watson D, Skodol AE. Initial construction of a maladaptive personality trait model and inventory for DSM-5. Psychol Med. 2012 Sep;42(9):1879-90. doi: 10.1017/S0033291711002674. Epub 2011 Dec 8.
PMID: 22153017BACKGROUNDKroger C, Harbeck S, Armbrust M, Kliem S. Effectiveness, response, and dropout of dialectical behavior therapy for borderline personality disorder in an inpatient setting. Behav Res Ther. 2013 Aug;51(8):411-6. doi: 10.1016/j.brat.2013.04.008. Epub 2013 May 14.
PMID: 23727659BACKGROUNDMehlum L. Mechanisms of change in dialectical behaviour therapy for people with borderline personality disorder. Curr Opin Psychol. 2021 Feb;37:89-93. doi: 10.1016/j.copsyc.2020.08.017. Epub 2020 Aug 25.
PMID: 32979766BACKGROUNDMcMain SF, Fitzpatrick S, Boritz T, Barnhart R, Links P, Streiner DL. Outcome Trajectories and Prognostic Factors for Suicide and Self-Harm Behaviors in Patients With Borderline Personality Disorder Following One Year of Outpatient Psychotherapy. J Pers Disord. 2018 Aug;32(4):497-512. doi: 10.1521/pedi_2017_31_309. Epub 2017 Sep 14.
PMID: 28910214BACKGROUNDMeuldijk D, McCarthy A, Bourke ME, Grenyer BF. The value of psychological treatment for borderline personality disorder: Systematic review and cost offset analysis of economic evaluations. PLoS One. 2017 Mar 1;12(3):e0171592. doi: 10.1371/journal.pone.0171592. eCollection 2017.
PMID: 28249032BACKGROUNDSchmitgen MM, Niedtfeld I, Schmitt R, Mancke F, Winter D, Schmahl C, Herpertz SC. Individualized treatment response prediction of dialectical behavior therapy for borderline personality disorder using multimodal magnetic resonance imaging. Brain Behav. 2019 Sep;9(9):e01384. doi: 10.1002/brb3.1384. Epub 2019 Aug 14.
PMID: 31414575BACKGROUNDLevi FA, Hrushesky WJ, Blomquist CH, Lakatua DJ, Haus E, Halberg F, Kennedy BJ. Reduction of cis-diamminedichloroplatinum nephrotoxicity in rats by optimal circadian drug timing. Cancer Res. 1982 Mar;42(3):950-5.
PMID: 7199382BACKGROUNDWoodbridge J, Reis S, Townsend ML, Hobby L, Grenyer BFS. Searching in the dark: Shining a light on some predictors of non-response to psychotherapy for borderline personality disorder. PLoS One. 2021 Jul 27;16(7):e0255055. doi: 10.1371/journal.pone.0255055. eCollection 2021.
PMID: 34314461BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 24, 2023
First Posted
October 30, 2023
Study Start
September 1, 2023
Primary Completion (Estimated)
August 31, 2027
Study Completion (Estimated)
August 31, 2027
Last Updated
June 25, 2025
Record last verified: 2025-06